We announced today that the first patient has been dosed in a Phase 2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer who are na?ve to TOP1-targeted therapies. CBX-12 is a first-in-class peptide-drug conjugate (PDC) that uses our proprietary alphalex? technology to enhance the delivery of exatecan, a potent, established TOP1 inhibitor, directly to tumor cells while limiting off-target effects. Learn more at https://bit.ly/4dJDq7S. #biotechnology #oncology #innovation #clinicaltrials
Cybrexa Therapeutics
生物技术研究
New Haven，CT 4,565 位关注者
Changing the paradigm for cancer treatment through the development of antigen-independent peptide drug conjugates.
关于我们
Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex? technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP? peptide, linker, and small molecule anti-cancer agent.?pHLIP? peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces.?pHLIP? was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc.?alphalex? represents the disruptive next generation in tumor targeting.?Early clinical trials of the company’s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology. For more information, visit www.cybrexa.com. Community Guidelines: https://bit.ly/3GI6AU0
- 网站
-
https://www.cybrexa.com
Cybrexa Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- New Haven，CT
- 类型
- 私人持股
- 创立
- 2017
- 领域
- biotech、oncology、Phase I、PARP inhibitor、DDR和drug development
地点
-
主要
获取路线
5 Science Park
US，CT，New Haven，06511
Cybrexa Therapeutics员工
动态
-
Today, we announced the final results of our Phase 1 study of CBX-12 in patients with advanced or metastatic solid tumors, which were presented at ESMO - European Society for Medical Oncology. The data demonstrate the broad activity of CBX-12 across six tumor types, with a strong response rate in TOP1-naive patients with ovarian and breast cancer, in addition to a favorable safety profile.? ? Based on this positive data, we have initiated a Phase 2 study of CBX-12 in platinum-resistant ovarian cancer. Read more about CBX-12’s potential for precision targeting and full results: https://bit.ly/3XqMkku ? #ESMO24 #Oncology #ClinicalTrials
-
We look forward to presenting full results from our Phase 1 study of peptide drug conjugate CBX-12 in advanced solid tumors at ESMO - European Society for Medical Oncology. As an antigen-independent therapy, CBX-12 may have broad utility in patients who are not eligible for antigen-targeted therapies. Join us at 12pm CET on Saturday, Sept 14, to learn more: https://bit.ly/3AY8P8K #oncology #ESMO24
-
-
#Cybrexa is leading the way in developing revolutionary therapies that target tumors while sparing healthy tissue. Our innovative alphalex? platform provides a new way to deliver drugs directly into cancer cells without depending on surface antigens. This cutting-edge approach has the potential to improve current #cancertherapeutics. We are dedicated to developing innovative solutions for patients fighting cancer. Stay tuned for some exciting clinical updates. Learn more about our advanced research and technology: https://bit.ly/3yCiugx. #drugdiscovery #smallmolecules #peptidedrugconjugates #oncology #lifesciences #WeAreCybrexa
-
At #Cybrexa, we are steadfastly committed to developing bold, innovative therapies that have the potential to shift the treatment paradigm. #DYK, our team of highly skilled scientists and clinical professionals is pioneering a platform of #cancertherapeutics designed to target tumors while sparing healthy tissue. This refined approach to intracellular delivery aims to enhance existing therapies and pave the way for new ones. Learn more: ?? https://bit.ly/3yB7osv. #drugdiscovery #smallmolecules #peptidedrugconjugates #oncology #lifesciences #CTBiotech #WeAreCybrexa
-
At #Cybrexa, we are steadfastly committed to developing bold, innovative therapies that have the potential to shift the treatment paradigm. #DYK, our team of highly skilled scientists and clinical professionals is pioneering a platform of #cancertherapeutics designed to target tumors while sparing healthy tissue. This refined approach to intracellular delivery aims to enhance existing therapies and pave the way for new ones. Learn more: ?? https://bit.ly/3yB7osv. #drugdiscovery #smallmolecules #peptidedrugconjugates #oncology #lifesciences #CTBiotech #WeAreCybrexa
-
Happy #IndependenceDay! Today, we proudly celebrate the freedom and independence made possible by the brave men and women who have fought, and continue to fight, for our country. #FourthofJuly #WeAreCybrexa?
-
#NEWS: Cybrexa Therapeutics today announced the appointment of former founding Alnylam CEO, John Maraganore, Ph.D., as Strategic Advisor to the Company’s Executive Leadership Team. In this role, Dr. Maraganore will provide strategic guidance, leveraging his extensive experience in the biopharma industry to support the advancement of #Cybrexa’s lead candidate and alphalex? technology platform. To read the press release in full, click here: https://bit.ly/4eAIIEa. #drugdiscovery #smallmolecules #peptidedrugconjugates #cancertherapeutics #CTBiotech #WeAreCybrexa
-
-
#DYK that while the #Cybrexa headquarters and most of our team members reside in #Connecticut, many of our dedicated and talented colleagues are located in several states across the US, including Florida, Georgia, Massachusetts, New Hampshire, New Jersey, Rhode Island, and Texas? Regardless of the distance, Cybrexa’s commitment to advancing our pipeline of #cancertherapeutics unites our team members as we work hard to bring hope to the #oncology community. Last month, some of our team members proudly wore teal ribbons on #WorldOvarianCancerDay to show solidarity and raise awareness for #ovariancancer. Check them out below. ?? #CTBiotech #drugdiscovery #smallmolecules #peptidedrugconjugates #WeAreCybrexa
-
On this #MemorialDay, we honor those who made the ultimate sacrifice to defend our country and uphold our freedom. We pay tribute to their selflessness and remember their legacy. We wish everyone a safe and meaningful Memorial Day weekend. #MDW24
-